🎉 That’s a wrap, folks! #EDxConf2024 may have come to an end, but our mission to revolutionize cancer early detection continues stronger than ever. 🚀 We are beyond grateful to all the speakers, attendees, sponsors, and partners who made this event unforgettable. Your ideas,

💡 Azra Raza (@AzraRazaMD) delivered a powerful talk on her mission to prevent and cure cancer effectively. Drawing from her book The First Cell, she emphasized the importance of identifying stress biomarkers that trigger cancer—shifting the focus from treating advanced disease

💡 Sylvia Plevritis (@PlevritisLab | @StanfordMed) and Cathie Sudlow (@HDR_UK) led today’s AI discussion session with @bissanao, @JensRittscher, and @suinleelab. 👉The discussion emphasized that predictive models are powerful, but AI must be treated like any diagnostic tool.

💡Su-In Lee (@suinleelab), pioneer in explainable AI (XAI), explained the importance of “prediction with explanation.” 🤖 She shared her lab’s work using XAI to: 🔹 Select optimal combination therapies 🔹 Understand drug synergy and hematopoietic “stemness” 🔹 Build on

💡 Jens Rittscher (@JensRittscher) is leveraging AI to analyze endoscopy images for Barrett’s esophagus. 🤖🔬 His lab focuses on automated quantification for data-driven phenotyping, with exciting potential to extend into spatial transcriptomics and thicker tissue

💡 Bissan Al-Lazikani (@bissanao) kicked off our AI session with an introduction to foundation models! 🤖 Her focus? Harnessing signal propagation and cooperativity to uncover key cancer features. With the power of multimodal data, she emphasized the potential of predictive

🚀🚀🚀 The final day of #EDxConf24 is about to kick off—let’s finish strong! 💪 Still Prima (@PDSinawang) reporting. Check out the agenda 👉 https://t.co/GVDo2yO6c8 It’s not goodbye yet, but huge thanks to our amazing sponsors and partners for making this event happen! 🙌

🌆 Day 2 wrapped up with a thrilling finale! Professor Antonis Antoniou (@antonis02 | @Cambridge_Uni) was honored with this year’s prestigious Don Listwin Award 🏆🎉 We hope everyone enjoyed the evening celebrations! 🥂✨ #DonListwinAward #CancerResearch #CelebratingExcellence

💬⚔️ Great Debate Recap: "Is research on early detection of rare cancers a waste of money?" Moderated by David Crosby (@CRUKresearch) FOR: Paul Spellman (@UCLA) argued that focusing on common cancers, responsible for 2/3 of deaths, has the greatest impact. He highlighted the

📚"We need to rewrite the playbook for evaluation of cancer screening tech", says Ruth Etzioni of @fredhutch in our panel discussion about the future of evaluation of cancer screening technologies. #EDxConf24 | @TomBeer | @ExactSciences | @UVA | @hilaryarobbins | @IARCWHO |

As part of our PPIE Flash Talks, Alice Groves speaks about the #ACED Cohort study & shows that PPI and continued participant feedback has resulted in improved retention, engagement, and recruitment of participants. So, basically: 📈more data 🥼more samples 💻wider usability of

The 2024 Don Listwin Award for Outstanding Contribution to Cancer Early Detection winner is Antonis Antoniou, PhD. Congratulations, Dr. Antoniou! https://t.co/JbK90FLzY5 #EDxConf24 @OHSUKnight @CRUKresearch

💡 Rhian Gabe presented the TRANSFORM prostate cancer trial, addressing the balance between PSA screening benefits and the ongoing concern of overdiagnosis in the EU & UK. She emphasized that evolving MRI practices and integrating new technologies with risk stratification could

💡 Kate Brain highlighted key barriers to inclusion in clinical trials: accessibility and acceptability. Her message? We must value people as individuals and ensure diverse voices are included at every step of study design. 🌍🌏🌎🤝 #ClinicalTrials #InclusionMatters

💡 Tiffani Howard emphasized the critical role of community engagement in patient recruitment during clinical trials. “The message matters” underscores the importance of involving patient advocates and community advisory boards to ensure meaningful diversity and representation.

💡 Scott Bratman (@ScottBratman) shared clinical insights on using ctDNA for MRD detection, extending its applications to early cancer detection and pinpointing tissue of origin. 🧬💉 Another powerful example of how liquid biopsy is redefining the future of early cancer